Table 3. Base case results over a 15-year time horizon.
| Parameter | Empagliflozin group | Control group | Incremental analysis |
|---|---|---|---|
| Mean total cost ($) | 5,220.98 | 4,873.96 | 347.02 |
| Mean QALYs | 4.86 | 4.68 | 0.18 |
| ICER | – | – | 1,893.59 |
| Diabetes status | |||
| With diabetes | |||
| Mean total cost ($) | 5,213.28 | 5,958.60 | −745.31 |
| Mean QALYs | 4.62 | 4.35 | 0.27 |
| ICER | – | – | Dominant |
| Without diabetes | |||
| Mean total cost ($) | 5,221.50 | 4,830.90 | 390.60 |
| Mean QALYs | 5.12 | 4.97 | 0.15 |
| ICER | – | – | 2,568.15 |
QALYs, quality-adjusted life years; ICER, incremental cost-effectiveness ratio.